Takeda
NYSE TAK · Tokyo, Japan
Works in Cardiovascular · Dermatology · ENT · Genetic & rare · GI & liver · Hematology · Immunology · Infectious disease · Metabolic & endocrine · Musculoskeletal · Neurology · Oncology · Psychiatry · Renal & urogenital · Respiratory · Women's health
Takeda is a clinical trial sponsor based in Tokyo, Japan, listed as NYSE TAK. It has 123 active clinical trials with 97,731 planned participants, across 16 therapeutic areas. Since 2021 it has completed 307 trials and stopped 48 early. Its FDA record on file shows 1 inspection.
Trial track record · since 2021
FDA record
Recent FDA actions
Financials · NYSE TAK
Pipeline · 123 active trials
| Stage | Trial | Status |
|---|---|---|
On the market
37 approved drug applications with a product on the market.
Questions about Takeda
No warning letter naming Takeda is on file. FDA has published 1 inspection classification naming it.
FDA has posted 1 inspection classification naming Takeda. The latest inspection ended on 2026-04-10 and was classified NAI (no action indicated). FDA posts a classification after its review, often months after the inspection ended.
Takeda is lead sponsor of 123 active clinical trials on ClinicalTrials.gov, with 97,731 planned participants, in Cardiovascular, Dermatology, ENT, Genetic & rare and other areas. Since 2021 it has completed 307 trials and stopped 48 early.
Takeda is based in Tokyo, Japan and is listed as NYSE TAK. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Takeda; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-15.
The FDA record counts inspection classifications, warning letters and recalls FDA has published that name this company. Compare it with the industry in the free CDMO FDA inspection lookup.
Approve Suite is not affiliated with Takeda. Informational only.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.